JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: The discovery of druggable pathways that may be selectively required for CML stem cell survival has led to the repurposing of established non-TKI drugs such as interferon and JAK2 inhibitors as co-treatments with TKIs.